Johnson and Johnson to launch human clinical study of new crown candidate vaccine ahead of schedule in July

Read more: Clinical studies, scheduled to begin in September, are expected to start early in the second half of JulyJohnson and Johnson announces the acceleration of the development of a new coronal pneumonia virus candidate vaccine, and phase 1/2a human clinical studies will be launched in the second half of JulyJohnson and Johnson continues to increase production capacity and strengthen partnerships to meet corporate commitments and meet global needsJune 10, Johnson and Johnson announced that its pharmaceutical subsidiary, Janssen Pharmaceuticals, is accelerating the first human clinical study of the new coronavirus (SARS-CoV-2) recombinant vaccine Ad26.COV2-SClinical studies, originally scheduled to begin in September, are expected to start early in the second half of Julythis randomized double-blind, placebo-controlled phase 1/2a study will evaluate the safety, reactive (response to vaccination) and immunogenicity (immune response) of the candidate new coronavirus recombinant vaccine Ad26.COV2-SJohnson and Johnson plans to recruit 1,045 healthy adults between the ages of 18 and 55 and adults 65 and older in the United States and Belgium to conduct the studyJohnson and Johnson is in discussions with the National Institute of Allergy and Infectious Diseases (NIAID) to begin Phase III clinical studies of the new coronavirus recombinant vaccine Ad26.COV2-S ahead of schedule before the results of the Phase I study and approval by the registrywhile conducting clinical studies of the new coronavirus recombinant vaccine Ad26.COV2-S, Johnson and Johnson continues to increase its production capacity and is actively engaged in discussions with global partners to secure the worldwide availability of the vaccineJohnson and Johnson is committed to providing a billion doses of safe and effective vaccines to the world by 2021Johnson and Johnson's in-depth collaboration with the U.SBureau of Advanced Biomedical Research and Development (BARDA) has provided strong support for accelerating the development and production of the new crown vaccineBARDA is part of the Office of the Undersecretary for Prevention and Response (ASPR) of the U.SDepartment of Health and Human Services